Skip to main content
Top
Published in: International Journal of Clinical Oncology 1/2020

01-01-2020 | Original Article

Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma

Authors: Jingtai Zhi, Yu Wu, Linfei Hu, Jingzhu Zhao, Hui Liu, Xianhui Ruan, Xiukun Hou, Jun Zhang, Xiangqian Zheng, Ming Gao

Published in: International Journal of Clinical Oncology | Issue 1/2020

Login to get access

Abstract

Background

The aim of this study was to evaluate the prognostic veracity for disease-specific survival (DSS) of the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis staging system (TNM-8) compared with the seventh edition (TNM-7) in a Chinese population of patients with differentiated thyroid carcinoma (DTC) and to evaluate the impact of N1b redefinition and reclassification on prediction of survival.

Methods

A total of 569 DTC patients who underwent thyroid surgery in two Chinese hospitals were included in analysis to assess the predictive accuracy and N1b changes of TNM-8. Data from the Surveillance, Epidemiology and End Results (SEER) program were applied to validate the findings on N1b changes of TNM-8. Unadjusted DSS was calculated using the Kaplan–Meier method. Multivariable Cox proportional hazards models were used to evaluate the association of stage and lymph node metastasis (LNM) status with survival. The proportion of variation explained (PVE), Akaike information criterion (AIC), and Bayesian information criterion (BIC) were evaluated to compare model performance.

Results

When TNM-8 was applied, 39.7% of patients were downstaged relative to TMN-7. In comparison of TNM-7 and TMN-8, the PVE was 18.68% and 22.33%, the AIC was 704.22 and 680.50, and the BIC was 702.98 and 679.24, respectively. In 569 Chinese patients with DTC, levels I–V LNM was significantly related to poorer DSS compared with N0 and level VI LNM. Among patients aged ≥ 55 years, those with levels I–V and VII LNM had significantly worse DSS than those with N0 and Level VI LNM. In the SEER dataset, patients with levels I–V and VII LNM had significantly worse DSS compared with those with N0 and Level VI LNM, especially in older patients (age ≥ 55 years).

Conclusions

TNM-8 staged a significant number of Chinese patients into lower stages and improved the accuracy of predicting DSS compared with TNM-7. However, changes in lateral LNM definition and classification of TNM-8 have a significant prognostic implication for patients with DTC, especially older patients (≥ 55 years). Our data suggest that a modified TNM staging system would be more useful for predicting mortality and determining a proper treatment strategy in patients with DTC.
Appendix
Available only for authorised users
Literature
8.
go back to reference Leboulleux S, Rubino C, Baudin E et al (2005) Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90(10):5723–5729. https://doi.org/10.1210/jc.2005-0285 CrossRefPubMed Leboulleux S, Rubino C, Baudin E et al (2005) Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90(10):5723–5729. https://​doi.​org/​10.​1210/​jc.​2005-0285 CrossRefPubMed
9.
go back to reference Verburg FA, Mader U, Tanase K et al (2013) Life expectancy is reduced in differentiated thyroid cancer patients %3e/= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98(1):172–180. https://doi.org/10.1210/jc.2012-2458 CrossRefPubMed Verburg FA, Mader U, Tanase K et al (2013) Life expectancy is reduced in differentiated thyroid cancer patients %3e/= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98(1):172–180. https://​doi.​org/​10.​1210/​jc.​2012-2458 CrossRefPubMed
20.
go back to reference Beal SH, Chen SL, Schneider PD et al (2010) An evaluation of lymph node yield and lymph node ratio in well-differentiated thyroid carcinoma. Am Surg 76(1):28–32PubMed Beal SH, Chen SL, Schneider PD et al (2010) An evaluation of lymph node yield and lymph node ratio in well-differentiated thyroid carcinoma. Am Surg 76(1):28–32PubMed
Metadata
Title
Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma
Authors
Jingtai Zhi
Yu Wu
Linfei Hu
Jingzhu Zhao
Hui Liu
Xianhui Ruan
Xiukun Hou
Jun Zhang
Xiangqian Zheng
Ming Gao
Publication date
01-01-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 1/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01522-x

Other articles of this Issue 1/2020

International Journal of Clinical Oncology 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine